Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCLnow 19#
- Development stage
- Unknown
- Lead developer
- Sclnow Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal
01
Overview
SCLnow 19# is an investigational cell therapy product consisting of human umbilical cord-derived mesenchymal stem cells (UC-MSCs), developed by Sclnow Biotechnology Co., Ltd. It is specifically designed for the treatment of spinocerebellar ataxia (SCA), including types 1, 2, 3, and 6. The therapy is administered through a combination of intravenous infusion and intrathecal injection. SCLnow 19# is thought to exert its therapeutic effects through multiple mechanisms, including the secretion of neurotrophic factors, immunomodulation, and the promotion of neuronal survival, with a particular focus on protecting cerebellar Purkinje cells from degeneration. It is currently being evaluated in Phase 2 clinical trials to assess its safety and efficacy in improving balance and coordination in patients with these hereditary neurodegenerative disorders.
- Brand names
- iSCLife
- Other names
- umbilical cord mesenchymal stem cellsUC-MSChuman umbilical cord mesenchymal stem cells19#iSCLife®-SA
Beyond the preview
Go deeper on SCLnow 19#.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCLnow 19#.